Malignant Colon Neoplasm — Trials

Malignant Colon Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

1,196 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 225
Recruiting: 117
Ph III recruiting: 18
Growth YoY: −3.8%
Industry share: 14%
Top sponsor: M.D. Anderson Cancer Center
Termination share: 26.9%
Trials / 1,000 deaths: 5.5 USA 2023 cdc-uscs

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (139)

clinicaltrialsPublishedShowing 1–18 of 18 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07808151	Neoadjuvant Pembrolizumab and Porustobart in Resectable pMMR/MSS Colon Cancer	not yet recruiting	Phase 2	100	Solstice Oncology, Inc.INDUSTRY	6	Sep 8, 2026	clinicaltrials
NCT07224022	Cemiplimab With Fianlimab for Resectable Non-Metastatic Colon Cancer(NACho)	not yet recruiting	Phase 2	24	John Strickler, M.D.OTHER	0	Aug 27, 2026	clinicaltrials